Physician profile
Hammad Zafar
NPI 1215451778
$4,951.68
in general payments reported to CMS, 2019-2025
24 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.30 · 2023: $1,070 · 2024: $1,878 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,754 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,754.39 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,649.60 | 2023-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,068.16 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $428.56 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.21 | 2023-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $232.81 | 2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $146.97 | 2025 | Voquezna |
| Genzyme Corporation | $138.55 | 2024-2025 | |
| Gilead Sciences, INC. | $114.82 | 2023 | Vemlidy |
| E.R. Squibb & Sons, L.L.C. | $105.40 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $101.25 | 2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $100.26 | 2025 | Livmarli |
| Janssen Scientific Affairs, LLC | $100.12 | 2024 | Tremfya |
| Alnylam Pharmaceuticals INC. | $89.19 | 2024 | Amvuttra |
| Ardelyx, INC. | $67.61 | 2025 | Ibsrela |
| Erbe USA INC | $65.00 | 2025 | Vio3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $56.37 | 2023-2025 | Ocaliva |
| Celltrion USA INC. | $50.63 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $49.22 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $25.48 | 2025 | Iqirvo |
| Axonics, INC. | $24.69 | 2023 | Axonics |
| Orphalan INC | $23.82 | 2025 | Cuvrior |
| Lilly USA, LLC | $20.92 | 2024 | Omvoh |
| Coloplast Corp | $17.74 | 2025 | |
| Celgene Corporation | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.